Overview

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house product development with strategic partnerships, allowing it to build a diverse pipeline of drug candidates and utilize advanced technologies to meet medical needs. A key subsidiary, Genevant, specializes in RNA therapeutics, employing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Simplify's Take

What believers are saying

• Roivant's acquisition of Dermavant expands its dermatology portfolio, enhancing market presence.
• Collaboration with Bayer to create Pulmovant strengthens Roivant's position in pulmonary hypertension.
• Roivant's innovative portfolio and strategic partnerships make it a strong buy opportunity.

What critics are saying

• Integration challenges may arise from Roivant's acquisition of Dermavant.
• Failure of lupus treatment brepocitinib could impact investor confidence.
• Reliance on partnerships, like with Roche, poses risks if outcomes are not met.

What makes Roivant Sciences unique

• Roivant builds nimble biotech companies called Vants to streamline drug development.
• Genevant, a Roivant subsidiary, specializes in RNA therapeutics using proprietary delivery platforms.
• Roivant's unique business model combines in-house development with strategic partnerships.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$5211M

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:

SoftBankFounders Fund

Notable Investors:

SoftBankFounders Fund

$411,000,000

Spac IPO

Oct 2021

Spac IPO funding comparison data is currently unavailable. We're working to provide this information soon!

Spac IPO Funding Comparison

Coming Soon

View all funding stages